161 related articles for article (PubMed ID: 9261526)
21. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
[TBL] [Abstract][Full Text] [Related]
22. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cisplatin chronotoxicity related to reduced glutathione in mice.
Boughattas NA; Li XM; Filipski J; Lemaigre G; Filipski E; Bouzouita K; Belhadj O; Lévi F
Hum Exp Toxicol; 1996 Jul; 15(7):563-72. PubMed ID: 8818709
[TBL] [Abstract][Full Text] [Related]
24. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin.
Giacomelli S; Gallo D; Apollonio P; Ferlini C; Distefano M; Morazzoni P; Riva A; Bombardelli E; Mancuso S; Scambia G
Life Sci; 2002 Feb; 70(12):1447-59. PubMed ID: 11883719
[TBL] [Abstract][Full Text] [Related]
25. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
26. [A clinical phase III trial of MR-20 in gynecologic nephrotoxicity of cisplatin--a comparative study in MR-20-treated and control patients on cyclical intermittent cisplatin treatment].
Ochiai K; Ikeda M; Kobayashi H; Nishimura H; Shibasaki T; Sakai O; Oh-hashi Y; Terashima Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):713-22. PubMed ID: 9571969
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Olt G; Lentz SS; Bell J
Gynecol Oncol; 2003 Sep; 90(3):581-6. PubMed ID: 13678728
[TBL] [Abstract][Full Text] [Related]
28. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
Gurney H; Crowther D; Anderson H; Murphy D; Prendiville J; Ranson M; Mayor P; Swindell R; Buckley CH; Tindall VR
Ann Oncol; 1990 Nov; 1(6):427-33. PubMed ID: 2083186
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
30. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
[TBL] [Abstract][Full Text] [Related]
31. High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results.
Bruzzone M; Conte PF; Chiara S; Carnino F; Giaccone G; Conio A; Bentivoglio G; Pescetto G; Rosso R
Chemioterapia; 1985 Apr; 4(2):139-42. PubMed ID: 3891114
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer.
Sagae S; Ishioka S; Fukunaka N; Terasawa K; Kobayashi K; Sugimura M; Nishioka Y; Kudo R; Minami M
Oncology; 2003; 64(1):46-53. PubMed ID: 12457031
[TBL] [Abstract][Full Text] [Related]
33. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
34. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
35. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
González Barón M; Chacón JI; García Girón C; Ordóñez Gallego A; García de Paredes ML; Feliu J; Zamora P; Herranz C; Garrido P; Artal A
Acta Oncol; 1991; 30(5):623-7. PubMed ID: 1892680
[TBL] [Abstract][Full Text] [Related]
37. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
38. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
Hospers GA; Eisenhauer EA; de Vries EG
Br J Cancer; 1999 May; 80(5-6):629-38. PubMed ID: 10360638
[TBL] [Abstract][Full Text] [Related]
39. Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry. Evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats anc cancer patients.
Bernareggi A; Torti L; Facino RM; Carini M; Depta G; Casetta B; Farrell N; Spadacini S; Ceserani R; Tognella S
J Chromatogr B Biomed Appl; 1995 Jul; 669(2):247-63. PubMed ID: 7581901
[TBL] [Abstract][Full Text] [Related]
40. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]